https://scholars.lib.ntu.edu.tw/handle/123456789/604454
標題: | Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study | 作者: | Krop, Ian E Im, Seock-Ah Barrios, Carlos Bonnefoi, Hervé Gralow, Julie Toi, Masakazu Ellis, Paul A Gianni, Luca Swain, Sandra M Im, Young-Hyuck De Laurentiis, Michelino Nowecki, Zbigniew CHIUN-SHENG HUANG Fehrenbacher, Louis Ito, Yoshinori Shah, Jigna Boulet, Thomas Liu, Haiying Macharia, Harrison Trask, Peter Song, Chunyan Winer, Eric P Harbeck, Nadia |
公開日期: | 2022 | 卷: | 40 | 期: | 5 | 來源出版物: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 摘要: | We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/604454 | ISSN: | 0732183X | DOI: | 10.1200/JCO.21.00896 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。